BioNTech and Fosun Pharma to Supply ~10M Doses of COVID-19 Vaccine to Hong Kong and Macao


  • BioNTech and Fosun collaborated to supply 10M doses of their BNT162 mRNA-based vaccine candidate against COVID-19 to Hong Kong SAR and Macao SAR, once approved
  • Fosun Pharma has signed the Letter of Intent with Jacobson for contemplated distribution of 10M doses of a vaccine targeting COVID-19 in the Chinese market
  • On Mar 13, 2020, the companies collaborated to jointly develop and commercialize the vaccine in Mainland China, Hong Kong, and Macau SAR and the Taiwan region. The P-I study of BNT162b1 has been initiated in China  and enrolled 144 participants

Click here ­to­ read full press release/ article | Ref: BioNTech | Image: StraitTimes